Jessica Riceberg
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Cancer-related Molecular Pathways, Protein Degradation and Inhibitors, Immunotherapy and Immune Responses, Peptidase Inhibition and Analysis
Most-Cited Works
- → A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment(2018)441 cited
- → Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor(2017)223 cited
- → Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer(2021)197 cited
- → A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models(2021)131 cited
- → Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924(2012)108 cited
- → Characterization of the Loss of SUMO Pathway Function on Cancer Cells and Tumor Proliferation(2015)60 cited
- → Disulfide bond‐stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays(2006)42 cited
- → Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2(2018)3 cited
- → Cellular and biochemical characterization of an inhibitor of the Ubiquitin Activating Enzyme (UAE)(2011)1 cited
- → A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment(2024)